Rare diseases
Investigational molecules
Locations
Scheelevagen 27, 223 63 Lund, Sweden
Cantargia AB’s clinical research activity is centered on advanced triple negative breast cancer, with interest in treatment strategies for a difficult-to-treat breast cancer subtype lacking common hormone and HER2 targets.
The sponsor’s work in this area reflects a focus on therapeutic options for aggressive disease with limited targeted treatment choices.
Cantargia AB runs clinical trials in conditions such as Triple negative breast cancer, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
SpainIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
